



AFRICAN JOURNAL OF CLINICAL AND EXPERIMENTAL MICROBIOLOGY   JANUARY  2009   ISBN 1595-689X    VOL10(1) 
AJCEM/2008103/20906      -http://www.ajol.info/journals/ajcem 
COPYRIGHT 2009  
AFR. J. CLN. EXPER. MICROBIOL. 10(1): 38 - 46 
PHARMACOECONOMIC EVALUATION OF DOXYCYCLINE AND 
TETRACYCLINE IN THE TREATMENT OF CHLAMYDIAL 
IMPLICATED NON-GONOCOCCAL URETHRITIS IN A TERTIARY 
HEALTHCARE INSTITUTION IN NIGERIA. 
 
*  Giwa A1,  Osagbemi GK2,    Olayinka BO3,   Giwa HBF4. 1 Department of Clinical Pharmacy and Pharmacy 
Administration, faculty of Pharmacy, University of Maiduguri, Nigeria. 2 Department of Epidemiology and 
Community Health, College of Health Sciences, University of Ilorin, Nigeria; 3 Department Pharmaceutics 
and Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, 
Nigeria and 4 Department of Pharmacy, University of Ilorin Teaching Hospital, Nigeria 
*  Correspondence Email:  abdulganiyugiwa@yahoo.com 
 
ABSTRACT 
With depressing nature of economy in many countries such as Nigeria where per capita income 
is low, there is need for utmost consideration for cost containment measures.   
Objective: The objective of this study is to conduct pharmacoeconomic   evaluation of two anti-
chlamydial indicated non-gonococcal urethritis therapeutic options and to make 
recommendations for inclusion of economic evaluation of drug therapies in health policy 
formulations and decision making. 
Methods: Cost effectiveness analysis was carried out retrospectively for prescribed/dispensed 
antibacterials to out-patients with chlamydial implicated non-gonococcal urethritis among 
other infectious diseases, by examining out-patient case notes between 2005 and 2007 in 
Ahmadu Bello University Teaching Hospital, Zaria Nigeria. 
Results : The result shows that doxycycline costs N1.33/unit of effectiveness while tetracycline 
costs N2.77/unit of effectiveness in the treatment of chlamydial implicated non-gonococcal 
urethritis.    Doxycycline is therefore more cost effective than tetracycline capsules.  Subjecting 
the costs and effectiveness to sensitivity analysis did not change this conclusion.  There is 
statistically significant difference in the effectiveness (outcome) of doxycycline (78.8%) and 
tetracycline (58.7%)     ( x2 =9.4; p<0.05)  There is therefore association between effectiveness and 
therapeutic option chosen with doxycycline being a more cost-effective option.  The result is 
significant because doxycycline is not currently included in the Essential Drug list of Nigeria1.  
However, the result is in agreement with Zimbabwean Essential Drug list which recommended 
that tetracycline be replaced by doxycycline in all indications and should be used only when 
doxycycline is not available2.  Also doxycycline is a drug of choice for other disease like 
gonorrhorea and syphilis in non-pregnant women2.  It was concluded that Doxycycline 100mg 
bd x 1/52 is more cost effective than Tetracycline 500mg qid x 1/52 in the treatment of chlamydial 
implicated non-gonococcal urethritis.  Adoption of economic evaluation of drug therapies in 
Nigeria Health policy formulation and decisions is likely to enhance overall Health System cost 
effectiveness. 
KEYWORDS: Pharmacoeconomics, Cost effectiveness analysis, Doxycycline, Tetracycline, Non-
gonocccal Urethritis. 
   
 
INTRODUCTION:  
The advancement in medical 
technology (both diagnostic and 
therapeutic options) have complicated 
the financial burden of Health Systems.  
Although they offer the potential to 
improve quality of care, these advances 
have significantly increased Health 
Systems operating costs. In spite of all 
aforementioned inherent and obvious 
predicaments, public expectation from 
healthcare providers and government is 
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increasingly becoming higher on a daily 
basis (3, 4). 
Therefore, there is need for   a useful 
scientific intervention that can facilitate 
rational decision-making.  
Consequently, interest in research to 
assess the outcomes of healthcare has 
been on the increase.  Medical, ethical 
and societal concerns about costs, access 
and quality of care are also 
motivating healthcare practitioners to 
consider more compressive model for 
medical decision-making. All these 
trends have led to the evolution of 
Pharmacoeconomic, a relatively new 
discipline in Pharmacy (5, 6).     
Cost-effectiveness analysis, a form of 
Pharmacoeconomics tool appears more 
effective if applied properly in 
therapeutic decision-making.  The 
various outcomes of therapy namely; 
economic, clinical and humanistic 
(psychosocial) are considered (7). A 
comparative cost and outcome 
evaluation was carried out for 
Doxycycline and Tetracycline in the 
treatment of chlamydial implicated non-
gonococcal urethritis in Ahmadu Bello 
University Teaching Hospital, Zaria, 
Nigeria. 
 
MATERIAL AND METHODS   
Time and motion studies in conjunction 
with standard cost-accounting 
techniques were used in this 
retrospective study. 
Patients 
The analysis addressed adult 
outpatients in Out-Patient Department 
Ahmadu Bello University Teaching 
Hospital, Zaria, Nigeria with 
chlamydial implicated non-gonococcal 
urethritis among other infectious 
disease confirmed by necessary 
diagnostic tools (Table 3). 
Data Collection 
One thousand and eighteen (1018) 
outpatient case notes for selected 
diseases were consecutively examined 
using diagnostic coding cards.  These 
were essentially diseases that had 
antibacterial agents as the mainstay of 
therapy.  One hundred and forty eight 
(148) of the patients suffered from 
chlamydial implicated non-gonococcal 
urethritis. 
In all, 1527 dispensed prescriptions 
were sampled systematically and 
examined. Relevant information were 
extracted and recorded. These included 
prescribed/dispensed drugs between 
year 2005 and 2007.  Others were 
dosage, duration of therapy, patient 
demographic data, diagnosis, 
concurrent illness, diagnosis tests ( if 
any), physician’s remark on each visits 
and cost of drugs. 
Computation of Data 
The cost per Defined Daily Dosage 
(DDD) of each antibacterial was 
calculated.  DDD units are 
recommended by World Health 
Organization (WHO) for analysis of 
drug use.  DDD represents the usual 
daily dosage of antibacterial per day (8). 
Cost-effectiveness Analysis 
Analysis of costs in monetary units and 
effectiveness in natural units 
(eradication of bacteria and  clinical 
cure) were carried out. 
xl 
 
Conduction of cost-effectiveness 
analysis  (9, 10)         
Definition of Pharmacoeconomic 
problem:  Should option I or II be 
recommended as therapy of choice for 
the treatment of chlamydial implicated 
non-gonococcal urethritis? (Table 3) 
Definition of the goals and objective of 
problem situation:  The objective was to 
determine which of the treatment 
options provide greater value for 
money for using effectiveness rating 
(Table 4), decision analysis(Table 5) cost 
of therapy (Table 6) and cost 
effectiveness analysis table (Table 7). 
 
Perspective:  Economic perspective of 
the Health institution was chosen since 
the drugs were prescribed there.   
However, patient perspective was 
considered where necessary. 
Enumeration of the different ways to 
achieve the objective: (Table 4) 
Consideration of available/preferred 
treatment options was made between 
doxycycline and tetracycline. 
Determination of cost of therapy 
Only direct medical costs were included 
in the analysis.  These included 
overhead and operating costs such as 
acquisition costs of drugs, staff time 
(costs associated with preparation and 
dispensing of the product) where it 
differs from the two options considered.  
Others include equipment, disposables 
and transport costs to patients where 
applicable.  The cost per defined daily 
dosage (C/DDD) of each drug was used 
(Table 6).   
Time and motion studies were carried 
out for Pharmacists that differ between 
each option.  There was no statistically 
significant difference between the 
frequencies of Physician visits among 
the two treatment options considered, 
being outpatients. 
The time and motion studies involved 
observing the actual work of each 
personnel including dispensing of 
capsule.  Each activity was timed using 
a stopwatch and the average time for 10 
random observations for the completion 
of the task was determined. 
The mean salary for the healthcare 
personnel was obtained from the 
Accounts section of the hospital. 
 
Mean salary/sec =                      annual salary 
                               Hours/week x Number of weeks/annum x 360 
The individual costs were converted into cost per dosage regimen. 
DiscountingNo adjustment for inflation 
or discounting was made for the 
analysis.  Costs were fairly stable and 
both options were used within each 
year under review.  However, slight 
variation over the period under review  
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in some cases led to the use of mean 
cost of each option. 
Consequences  (Outcomes of each 
treatment option). 
The literature was reviewed for positive 
and negative outcomes of each 
treatment options (Table 4) (11-14)  
Sensitivity Analysis     
Sensitivity analysis was performed to 
test whether the decision changes when 
specific variables altered within 
reasonable range in favour of less cost 
effective option.  This was carried out 
for the cost of treatment options and 
effectiveness (Table 8) 
Data Analysis 
Statistical analysis was carried out on 
the results obtained.  The effectiveness 
rating (percentage, proportion) was 
compared by the use of Chi-square 
analysis.    
          
RESULTS  
Table 1: COST EFFECTIVENESS ANALYSIS (CEA) 
   Cost of therapy  Effectiveness (E)  CEA (C/E) 
Doxycycline Option I 
100mg b.d x 1/52 
N104.3 78.8 N1.33/Unit of effectiveness  
Tetracycline (Option II)  
500mg q.i.d x 1/57 
N62.5 58.7 N2.77/Unit effectiveness  
 
Using Doxycyline capsule (option I) in 
the treatment of chlamydial implicated 
non-gonococcal urethritis at a full 
course of 100mg bd x 1/52 cost N104.3 
with effectiveness measure of 78.8 and 
cost effectiveness of N1.33/unit of 
effectiveness.  While tetracycline 
capsules at a full course of 500mg qid x 
1/52 (option II) when used for treatment 
of same condition cost N162.5 with 
effectiveness measure of 58.7 and cost 
effectiveness of N2.77/unit of 
effectiveness. 
Doxycyline capsules 100mg qid 1/52 is 
therefore cheaper per unit of 
effectiveness than tetracycline capsules 
500mg qid x 1/52 in the chlamydial 
implicated non-gonococcal urethritis 
and therefore more cost effective. 
There is statistically significant 
difference in the effectiveness (outcome) 
of Doxycyline and tetracycline (58.7%) 
(X2 = 9.4; p< 0.05). There is therefore 
association between effectiveness and 
therapeutic option chosen.    
 
Table 2: SENSITIVITY ANALYSIS  
S/NO ALTERATION IN VARIABLE COST EFFECTIVENESS 
1 Increasing the cost of doxycycline by 50%  N1.99/unit of effectiveness  
2 Decreasing the cost of doxycycline by 40% N1.66/unit of effectiveness  
3 Increasing the effectiveness of tetracycline to 78.8 
(Doxycyline value)  
N2.006/unit of effectiveness  
 
Sensitivity analysis (what if analysis) 
indicates the decision still remains 
valid, confirming doxycycline to be 
more cost effective, despite alterations 
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made in favour of less cost effective Tetracycline.   
 
 
Table 3: Treatment Options For Cost- Effectiveness Analysis  
Diseases condition Diagnostic tools Treatment option 
Non-gonococcal urethritis where 
chlamydial  is implicated  
Objective evidence of urethra 
discharge (Expressed by milking or 
> 5PMIN/100 x field in the urethra 
secretion, with the exclusion of N. 
gonorrhea by Gram’s stain and/or 
culture  
Doxycycline capsules  
100mg bid x 1/52 
Tetracycline capsules 
500mg qid x 1/52   
    
TABLE 4:  EFFECTIVENESS RATING   
 
CRITERIA  CAP DOXYCYCLINE 
 (OPTION I ) 
VALUE  CAP TETRACYCLINE 
 (OPTION II) 
VALUE  





Assumption   
Broad-spectrum antibiotic.  Gram negative 
Gram-positive organisms and chlamydial are 
sensitive, as well as 70-90% of anaerobes.  More 
active for resistant organisms 
100% sensitivity of chlamydial infection 







Broad-spectrum antibiotic.  Gram 
negative Gram-positive organisms and 
chlamydial are sensitive, about 10%  
resistance for Gram-positive and 50% 
for some Gram-negative organisms 









2b Frequency of 
administration   
Oral absorption                           93% 
Pre-system metabolism                Nil  
Bioavailability                              93% 
Plasma t½  (range)                     18-22hrs 
Plasma protein binding               82-93% 
 









Oral absorption  irregular & 
incomplete  
Pre-system metabolism            Nil  
Bioavailability                         60% 
Plasma t½  (range)                 8-5hrs  












3.  Interaction  It can be taken with food or milk if gastric 
irritation is a problem although chelates 




It cannot be taken with food or milk 
because of irregular and incomplete 
oral absorption.  It is  a chelationg 




4.  Adverse Drug 





Safe in renal insufficiency 
Each negative effect assumed to be 10% 






Less safe in renal insufficiency 












Table 5: Table Of Decision Analysis.  
CAP. DOXYCYCLINE (OPTION I)  Cap. Tetracycline  








Value (%) Assigned Weight Criterion 
rating 
1.  Spectrum  of activity 
2a  Pharmacokinetics 
2b. Frequency of     administration. 
3.   Interaction 
4. Tolerability (100-DR%)   







































SUM OF CRITERIA RATINGS 
(EFFECTIVENESS MEASURE) 
 1.00 78.8  1.00 58.7 
 
TABLE 6: Cost Of Therapy 
Only direct medical costs, which included; drug acquisition cost and costs associated with 
dispensing were considered. 
OPTION I  
DOXYCYCLINE  CAPSULES  
OPTION II 
TETRACYCLINE CAPSULES 
Acquisition Cost = C/DDD x DOT in days = 100mg 
bid x 1/52   - 14 x 7 = 98.00 
 
Cost of dispensing by Pharmacist =  Mean 
salary/sec x time taken for dispensing ins seconds  = 
0.2680 x 24 = N6.43 
Total  cost = N104.43  
Acquisition Cost = 500mg  qid x 1/52  
= 20 x 7 = N140.00 
 
Cost of dispensing by Pharmacist =  0.2680 x 84 = 
N22.51 
Total Cost = N162.51 
 
Physician office visit and patient traveling cost is assumed to be the same for both options. 
 
Table 7: Cost Effectiveness Analysis (CEA)    
OPTION I DOXYCYCLINE  CAPSULES  OPTION II TETRACYCLINE CAPSULES 
Cost = 104:43, Effectiveness = 78.8 
 
CEA = 104:43 = N1.33/unit of effectiveness  
            78.8 
 
Cost = 162:51, Effectiveness = 58.7 
 
CEA = 162:51 = N2.77/unit of effectiveness  
            78.8 
 
 
Table 8 : Sensitivity Analysis    
i.     Increasing cost of doxycycline by 50% (156.65) 
 
    CEA  156.65   = N1.99 unit of effectiveness 
              78.8 
    ii.     Decreasing cost of tetracycline by 40% (97.51) 
 
    CEA  97.51   = N166 unit of effectiveness 
              58.7 
 iii.     Increasing the effectiveness of tetracycline to 78.8 (Doxycycline value) 
 
    CEA  162.51   = N2.06 unit of effectiveness 
              78.8 





The result of this study is significant 
because the Essential Drug List of 
Nigeria does not include doxycycline1 
in spite of its cost-effectiveness over 
tetracycline as shown in this study. 
With NAFDAC’s recent commitment to 
registration of good quality drugs, 
economic evaluations in form of 
pharmacoeconomic trials reports should 
be required along with clinical trials 
report for the inclusion of a drug on the 
Essential Drugs List.  With these, 
decisions for drug registration will be 
based on the principle that “if a drug is 
not better than a comparable product, it 
should not cost more.  If it is superior to 
existing therapies but more expensive (a 
common situation), and funds are 
available, any extra expenditure should 
represent “value for money” (15). 
The result of this study is in agreement 
with Zimbabwean Essential Drugs List 
which recommended that tetracycline 
be replaced by doxycycline in all 
indications, and should only be used 
when Doxycyline is not available (2).  
Also Doxycyline is a drug of choice for 
other disease like gonorrhea and 
syphilis in non-pregnant women2.  This 
result is also similar to the outcome of a 
comparative study for doxycycline and 
co-trimoxazole in the non-gonococcal 
urethritis where conclusion was drawn 
that Doxycyline is superior to co-
trimoxazole and may become the drug 
of choice for uncomplicated non-
gonococcal urethritis (16).  The findings 
of this study is in agreement with the 
report of the National Network for 
STD/HIV Prevention and Training 
Center that doxycycline at a course of 
100mg bid x 1/52 for treatment of 
Chlamydial infection has an efficacy of 
95-100%, lower cost and better 
tolerability than Erythomycin 2mg daily 
x 1/52   with 85-95% efficacy, higher cost 
and only fair tolerability (17)      
The statistically significant difference in 
the effectiveness of Doxycycline (78.8%) 
and tetracycline (58.7%) (X2= 9.4; 
p<0.05) appear to be due to difference in 
their economic clinical and humanistic 
outcomes (7). 
Doxycyline achieves bioavailability of 
93% after oral absorption while 
tetracycline due to irregular and 
incomplete oral absorption has 60% 
bioavailability (11). This and once daily 
or twice daily dose of doxycycline as 
compared with four times daily dose of 
tetracycline, significantly favours the 
effectiveness rating of doxycycline over 
tetracycline.  The fact that tetracycline 
cannot be taken with food or milk as 
compared with doxycycline which can 
be taken with food or milk if gastric 
irritation is a problem (14), also favours 
the effectiveness of doxycycline over 
tetracycline.  Doxycycline is also the 
least affected by the multivalent reports 
of resistance to tetracycline. In terms of 
tolerability, doxycycline is reported to 
be safer in renal insufficiency than 
tetracycline(11, 12, 13).  This also 
enhances effectiveness rating of 







The results of this work has shown that 
doxycycline capsules at a course of 
100mg bid x 1/52  is more cost effective 
than tetracycline capsules at 500mg qid 
x 1/52  for the treatment of chlamydial 
implicated non-gonococcal urethritis at 
p<0.05.  This is enough justification for 
ensuring that doxycycline is included in 
the revised Nigerian Essential Drug 
List.  Adoption of economic evaluation 
of drug therapies in National health 
policy formulation and decision is 
therefore likely to guarantee the overall 
Health System cost-effectiveness. 
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